TWI333955B - - Google Patents

Download PDF

Info

Publication number
TWI333955B
TWI333955B TW091111430A TW91111430A TWI333955B TW I333955 B TWI333955 B TW I333955B TW 091111430 A TW091111430 A TW 091111430A TW 91111430 A TW91111430 A TW 91111430A TW I333955 B TWI333955 B TW I333955B
Authority
TW
Taiwan
Prior art keywords
group
inhibitor
acid
general formula
nmr
Prior art date
Application number
TW091111430A
Other languages
English (en)
Chinese (zh)
Inventor
Shiohara Hiroaki
Fujikura Hideki
Fushimi Nobuhiko
Ito Fumiaki
Isaji Masayuki
Original Assignee
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical
Application granted granted Critical
Publication of TWI333955B publication Critical patent/TWI333955B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
TW091111430A 2001-05-30 2002-05-29 TWI333955B (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001163382 2001-05-30

Publications (1)

Publication Number Publication Date
TWI333955B true TWI333955B (enExample) 2010-12-01

Family

ID=19006365

Family Applications (1)

Application Number Title Priority Date Filing Date
TW091111430A TWI333955B (enExample) 2001-05-30 2002-05-29

Country Status (6)

Country Link
US (1) US7217697B2 (enExample)
EP (1) EP1400529A4 (enExample)
JP (1) JP4399251B2 (enExample)
CA (1) CA2448741C (enExample)
TW (1) TWI333955B (enExample)
WO (1) WO2002098893A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1020944C (zh) 1990-01-30 1993-05-26 阿图尔-费希尔股份公司费希尔厂 紧固件
WO2002044192A1 (en) * 2000-11-30 2002-06-06 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxybenzyl benzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
EP1389621A4 (en) 2001-04-27 2005-05-11 Ajinomoto Kk N-SUBSTITUTED PYRAZOLYL-O-GLYCOSIDE DERIVATIVES AND DIABETES CONTAINING THEREOF
US7956041B2 (en) * 2002-04-26 2011-06-07 Ajinomoto Co., Inc. Prophylactic and therapeutic agent of diabetes mellitus
WO2004019958A1 (ja) * 2002-08-27 2004-03-11 Kissei Pharmaceutical Co., Ltd. ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途
AU2003272903A1 (en) 2002-10-04 2004-04-23 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same
EP1568380A4 (en) * 2002-12-04 2009-10-21 Kissei Pharmaceutical PREVENTION OR TREATMENT OF DISEASES DUE TO HYPERGLYCEMIA
DE10258008B4 (de) * 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
US20040198800A1 (en) * 2002-12-19 2004-10-07 Geoffrey Allan Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents
AU2003289440A1 (en) * 2002-12-25 2004-07-22 Kissei Pharmaceutical Co., Ltd. Nitrogen-containing heterocycic derivatives, medicinal compositions containing the same and medicinal use thereof
JP2004300102A (ja) * 2003-03-31 2004-10-28 Kissei Pharmaceut Co Ltd 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
WO2004113359A1 (ja) 2003-06-20 2004-12-29 Kissei Pharmaceutical Co., Ltd. ピラゾール誘導体、それを含有する医薬組成物及びその製造中間体
EP1679965A4 (en) 2003-08-01 2009-05-27 Janssen Pharmaceutica Nv SUBSTITUTED ANELLIERED HETEROCYCLIC C-GLYCOSIDES
WO2005012243A2 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indole-o-glucosides
CA2549017A1 (en) 2003-08-01 2005-02-10 Mona Patel Substituted indazole-o-glucosides
AU2004261663A1 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides
CA2539032A1 (en) * 2003-08-26 2005-03-10 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-pirazoles, drugs containing said compounds the use and production method thereof
US7375090B2 (en) 2003-08-26 2008-05-20 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof
WO2005021039A1 (en) * 2003-08-29 2005-03-10 Cotherix, Inc. Combination of cicletanine and an oral antidiabetic and/or blood lipid-lowering agent for treating diabetes and metabolic syndrome
US7838552B2 (en) 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US7803838B2 (en) 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
TW200606129A (en) 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
DE102004048397B4 (de) * 2004-10-01 2007-08-16 Iongate Biosciences Gmbh Typ-SGLT1-Protein-Assay
US20070141174A1 (en) * 2005-01-13 2007-06-21 Navitas Pharma, Inc. Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
MX2007011360A (es) * 2005-03-17 2007-11-15 Kissei Pharmaceutical Proceso para la produccion de derivados de glucopiranosiloxipirazol.
JP4888840B2 (ja) * 2005-07-22 2012-02-29 味の素株式会社 ピラゾール−o−グリコシド誘導体の調製方法及び前記方法の新規中間体
UY30082A1 (es) 2006-01-11 2007-08-31 Boehringer Ingelheim Int Forma cristalina de 1-(1-metiletil)-4`-((2-fluoro-4-metoxifenil)metil)-5`- metil-1h-pirazol-3`-o-b-d-glucopiranosido, un metodo para su preparacion y el uso de la misma para preparar medicamentos
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
RU2437876C2 (ru) * 2006-05-19 2011-12-27 Тайсо Фармасьютикал Ко., Лтд. Соединение с-фенилглицитола для лечения диабета
KR20090023570A (ko) 2006-06-29 2009-03-05 다이쇼 세이야꾸 가부시끼가이샤 C-페닐 1-티오글루시톨 화합물
EP2103607A4 (en) 2006-12-14 2011-01-05 Taisho Pharmaceutical Co Ltd 1-phenyl-1-thio-D-GLUCITOLDERIVAT
ES2380408T3 (es) * 2008-08-28 2012-05-11 Pfizer Inc. Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
PE20120648A1 (es) 2009-02-23 2012-05-31 Taisho Pharmaceutical Co Ltd Compuestos de 4-isopropilfenilglucitol como inhibidores de sglt1
US8669380B2 (en) 2009-11-02 2014-03-11 Pfizer Inc. Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
US9161945B2 (en) 2010-08-20 2015-10-20 Taisho Pharmaceutical Co., Ltd. 4-isopropyl-6-methoxyphenyl glucitol compound
PH12013500302A1 (en) 2010-08-20 2017-05-19 Taisho Pharmaceutical Co Ltd Crystal form of 4-isopropylphenyl glucitol compound and process for production thereof
WO2012176804A1 (ja) * 2011-06-20 2012-12-27 キッセイ薬品工業株式会社 グルコピラノシルオキシピラゾール誘導体
UA113086C2 (xx) 2012-05-10 2016-12-12 Піразольні сполуки як інгібітори sglt1
TW201425326A (zh) 2012-10-05 2014-07-01 Lilly Co Eli 新穎脲化合物
AR098670A1 (es) 2013-11-08 2016-06-08 Lilly Co Eli Inhibidor de sglt1

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1213296B1 (en) * 1999-08-31 2004-04-14 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof
AR031078A1 (es) * 1999-10-29 2003-09-10 Takeda Pharmaceutical Compuesto acido (e)-4-[4-(5-metil-2-fenil-4-oxalilmetoxi)benziloxiimino]-4-fenilbutirico cristalino, composicion farmaceutica que lo comprende y su uso para fabricar esta ultima.
CA2390928A1 (en) * 1999-11-10 2001-05-17 Takeda Chemical Industries, Ltd. Alkoxyiminoalkanoic acid derivatives
WO2002036602A1 (en) * 2000-11-02 2002-05-10 Ajinomoto Co., Inc. Novel pyrazole derivatives and diabetes remedies containing the same
SK287786B6 (sk) 2000-12-28 2011-09-05 Kissei Pharmaceutical Co., Ltd. Glukopyranosyloxypyrazolový derivát, farmaceutická kompozícia alebo kombinácia s jeho obsahom a ich použitie
EP1364957B1 (en) 2001-02-26 2008-12-31 Kissei Pharmaceutical Co., Ltd. Glycopyranosyloxypyrazole derivatives and medicinal use thereof
WO2002068440A1 (en) 2001-02-27 2002-09-06 Kissei Pharmaceutical Co., Ltd. Glycopyranosyloxypyrazole derivatives and medicinal use thereof
EP1389621A4 (en) 2001-04-27 2005-05-11 Ajinomoto Kk N-SUBSTITUTED PYRAZOLYL-O-GLYCOSIDE DERIVATIVES AND DIABETES CONTAINING THEREOF

Also Published As

Publication number Publication date
WO2002098893A1 (en) 2002-12-12
CA2448741A1 (en) 2002-12-12
JP4399251B2 (ja) 2010-01-13
EP1400529A4 (en) 2007-12-19
US20040176308A1 (en) 2004-09-09
EP1400529A1 (en) 2004-03-24
JPWO2002098893A1 (ja) 2004-09-16
US7217697B2 (en) 2007-05-15
CA2448741C (en) 2010-06-22

Similar Documents

Publication Publication Date Title
TWI249535B (en) Glucopyranosyloxypyrazole derivatives and medicinal use thereof
JP4399251B2 (ja) グルコピラノシルオキシピラゾール誘導体、それを含有する医薬組成物、その医薬用途およびその製造中間体
TWI341843B (enExample)
KR100882179B1 (ko) 함질소 복소환 유도체, 그것을 함유하는 의약 조성물, 그의약 용도 및 그 제조 중간체
KR101214433B1 (ko) 축합 헤테로환 유도체, 그것을 함유하는 의약 조성물 및 그의약 용도
KR101141558B1 (ko) 축합 복소환 유도체, 그것을 함유하는 의약 조성물 및 그의약 용도
TWI231298B (en) Glucopyranosyloxypyrazole derivatives and use thereof in medicines
ES2319263T3 (es) Derivados de glucopiranosilooxipirazol y su utilizacion como medicamentos.
JP4606876B2 (ja) ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途
KR101170715B1 (ko) 축합 복소환 유도체, 그것을 함유하는 의약조성물 및 그의약용도
JP4679155B2 (ja) 含窒素複素環誘導体、それを含有する医薬組成物およびその医薬用途
JP4278983B2 (ja) グルコピラノシルオキシベンジルベンゼン誘導体及びその医薬用途
TWI351281B (en) Nitrogenous fused-ring derivatives,medicinal compo
JP4708187B2 (ja) ピラゾール誘導体、それを含有する医薬組成物及びその製造中間体
JP5020065B2 (ja) 1−置換−7−(β−D−グリコピラノシルオキシ)(アザ)インドール化合物、及びそれを含有する医薬
JP2004137245A (ja) ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
JPWO2003011880A1 (ja) グルコピラノシルオキシベンジルベンゼン誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
JP2004196788A (ja) ベンジルフェノール誘導体、それを含有する医薬組成物およびその医薬用途
JP2011529897A (ja) 化合物と使用
WO2005095373A1 (ja) ナフタレン誘導体、それを含有する医薬組成物およびその医薬用途
HK1068895B (en) Nitrogen-containing heterocyclic derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees